Clinical trials: Human Immunodeficiency Virus Type 1
HIV-1 Infection
4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients
Evaluate after 48 weeks, the capacity of a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment, in HIV-1 treated patients with undetectable viral load for at least 12 months and continuous…
- Trial name
- ANRS162-4D (NCT02157311)
- Testing
- Four consecutive days on treatment and 3 days off
- Where
- 17 sites in France
- Volunteers
- 100 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants
This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4004280 in healthy adults.
- Trial name
- NCT05163522
- Testing
- VH4004280, Midazolam
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine
The intensification with maraviroc in recently HIV-1-infected patients of a preferred gold-standard triple therapy composed of raltegravir plus tenofovir/emtricitabine could accelerate the decay of the HIV-1 reservoir in latently…
- Trial name
- NCT00808002
- Testing
- Raltegravir, Maraviroc, Tenofovir/Emtricitabine
- Where
- 2 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Germans Trias i Pujol Hospital
Chronic Hepatitis B
Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet With Viread® Tablet
The purpose of this study is to compare the safety and pharmacokinetics of CKD-390(Tenofovir Disoproxil Aspartate) and Viread® tablet(Tenofovir Disoproxil Fumarate) in healthy male volunteers.
- Trial name
- NCT02589457
- Testing
- CKD-390, Viread® tablet
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Chong Kun Dang Pharmaceutical
HIV Infections
Pharmacokinetic Study of 2 Doses of ATV/r OD + 2 NRTIs in Thai HIV-1 Infected Patients
Several studies from HIV-NAT have demonstrated high nevirapine, indinavir, saquinavir and lopinavir/r levels when compared to Caucasian patients.
- Trial name
- NCT00411957
- Testing
- Atazanavir
- Where
- Thailand
- Volunteers
- 22 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
HIV Infections
Study Evaluating Vaccine in Adults With HIV
The main purpose of this study is to learn whether the study vaccine and the adjuvants(drugs that are used to help immune response) have an acceptable safety profile in treating individuals with HIV.
- Trial name
- NCT00195312
- Testing
- HIV-1 gag DNA (formulated with bupivacaine), IL-15 DNA (formulated with bupivacaine), IL-12 DNA (formulated with bupivacaine)
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 91 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
HIV I Infection
Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF
Phase 4, randomized, open-label study to evaluate the efficacy, safety and tolerability of switching virologically suppressed adults living with HIV on bictegravir/tenofovir alafenamide/emtricitabine to dolutegravir/lamivudine
- Trial name
- DYAD (NCT04585737)
- Testing
- Dolutegravir / Lamivudine Pill, Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Charlotte-Paige Rolle, MD
Hepatitis C, HIV Infections
Immune Response to Hepatitis C Virus
The purpose of the study is to investigate the immune response to hepatitis C virus to determine why some people clear the virus and others develop chronic infection.
- Trial name
- NCT00165919
- Testing
- None. Not a clinical trial. Specimens taken for basic research in laboratory.
- Volunteers
- healthy volunteers welcome
- Sponsor
- Emory University
HIV Viremia, HIV -1 Infection
PERSON-CENTERED APPROACHES TO VIREMIA: CONNECTION, RAPPORT, AND ENGAGEMENT STUDY
The study aims to increase the reach of the person-centred interpersonal practices by developing and accessing a tailored, scalable, and sustainable approach that meets the distinctive needs of populations identified as most…
- Trial name
- P-CoRE (NCT07021092)
- Testing
- Interventions will be developed in aim 2 of the study.
- Where
- 2 sites in Zambia
- Volunteers
- 3,000 people
- Sponsor
- Centre for Infectious Disease Research in Zambia
HIV Infections
Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women
Prospective, open, single-arm trial of dolutegravir-tenofovir and emtricitabine or lamivudine (DTG-TDF-FTC or 3TC) in antiretroviral (ART) naïve HIV transgender women (TGW).
- Trial name
- TRANSViiV (NCT03033836)
- Testing
- ARV treatment
- Where
- Argentina
- Volunteers
- 60 people
- Sponsor
- Fundación Huésped
Infection, Human Immunodeficiency Virus I
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects
The purpose of this study is to evaluate the safety and efficacy of the CCR5 antagonist GW873140 or placebo in combination with an optimized background regimen in treatment-experienced HIV-infected subjects with R5-tropic virus
- Trial name
- NCT00197145
- Testing
- GW873140
- Where
- 55 sites in United States, Canada and 1 more
- Volunteers
- 24 people
- Sponsor
- ViiV Healthcare
HIV Infection
CLEAC (Comparison of Late Versus Early Antiretroviral Therapy in HIV-infected Children)
The study aims to define and compare the immunological characteristics (lymphocyte subpopulations, specific immunity against HIV, lymphocyte activation, inflammatory parameters) and the virological characteristics (study of viral…
- Trial name
- CLEAC (NCT02674867)
- Testing
- Blood draw
- Where
- 11 sites in France
- Volunteers
- 80 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV -1 Infection
Analyses of Newly Diagnosed HIV Infection in Hong Kong
The goal of the project is to determine the epidemiologic status and changing patterns of HIV infection in Hong Kong. The main question it aims to answer is: what is the molecular pattern and burden of HIV-1 infections over the…
- Trial name
- NCT07725042
- Where
- Hong Kong
- Volunteers
- 720 people
- Sponsor
- Chinese University of Hong Kong
HIV-1-infection
The Medicines Optimisation Review Toolkit Evaluation in HIV Outpatients
Multicentre, randomised (1:1), controlled, open (not blinded) comparison of MOR toolkit (intervention) with standard pharmaceutical care (control)
- Trial name
- MOR (NCT03340077)
- Testing
- Medicines Optimisation Review toolkit, Standard of Care
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Brighton and Sussex University Hospitals NHS Trust
HIV Infections
Development of a New HIV Vaccine
The purpose of the study is to determine the safety of a new HIV vaccine and to evaluate the immune response to the vaccine. Only some HIV genes are used to make the vaccine and therefore the vaccine cannot itself cause HIV or…
- Trial name
- NCT00051922
- Testing
- PolyEnv1
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Probiotic Visbiome for Inflammation and Translocation in HIV II
Modern antiretroviral therapy (ART) has transformed the clinical care and lived experience of HIV infection. However, increased rates of adverse health conditions that are related to immune activation, such as cardiovascular…
- Trial name
- PROOV IT II (NCT02441231)
- Testing
- Visbiome
- Where
- 2 sites in Canada
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
Healthy
Safety and Immunogenicity of Candidate HIV Vaccines Given Sequentially
The primary object of the study is to assess the safety profile of candidate vaccines ChAdOx1.HTI and MVA.HTI administered sequentially in healthy HIV-1/2 negative adult volunteers.
- Trial name
- NCT04563377
- Testing
- ChAdOx1.HTI and MVA.HTI
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Oxford
HIV Infections
Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)
The purpose of this study is to compare the proportion of subjects with HIV-1 RNA viral load < 50 c/mL through Week 48 of the Maintenance Phase among HIV-infected subjects with an initial undetectable viral load following an…
- Trial name
- INDUMA (NCT00207142)
- Testing
- Atazanavir + 2 NRTIs, Atazanavir + Ritonavir + 2 NRTIs
- Where
- 27 sites in Estonia, France and 8 more
- Volunteers
- 252 people
- Sponsor
- Bristol-Myers Squibb
Men or Transgender Women Who Have Sex With Men
HIV Self-Testing AND Uptake and Retention of PrEP Among Older Adolescent MSM and TGW
This will be a prospective study that will enroll up to 600 older adolescent MSM and TGW from community-based clinics in Bangkok, Chonburi, Chiang Mai, and Songkhla.
- Trial name
- NCT03745495
- Where
- 7 sites in Thailand
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Thai Red Cross AIDS Research Centre
HIV Infections
Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults
This study will evaluate the safety of and the body's immune response to experimental HIV vaccine regimens using different vaccine priming combination, and boosting with the vaccines NYVAC and AIDSVAX® B/E.
- Trial name
- NCT01799954
- Testing
- DNA-HIV-PT123, NYVAC-HIV-PT1, NYVAC-HIV-PT4
- Where
- Switzerland
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.